MaxCyte (MXCT) News Today $3.49 +0.16 (+4.80%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsNovember 13, 2024 | globenewswire.comMaxCyte’s Strong Performance and Growth Potential Justifies Buy Rating by Mark MassaroNovember 12, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for MaxCyte Issued By William BlairMaxCyte, Inc. (NASDAQ:MXCT - Free Report) - William Blair lifted their FY2024 earnings estimates for MaxCyte in a research report issued to clients and investors on Thursday, November 7th. William Blair analyst M. Larew now expects that the company will earn ($0.43) per share for the year, up froNovember 11, 2024 | marketbeat.comMaxCyte Weighs Delisting from AIM to Prioritize Nasdaq: Potential Benefits and Risks AheadNovember 8, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT)November 7, 2024 | markets.businessinsider.comMaxCyte’s Q3 Performance and Strategic Initiatives Signal Strong Growth Potential and Investment OpportunityNovember 7, 2024 | markets.businessinsider.comMaxCyte, Inc. (MXCT) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comMaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 GuidanceNovember 6, 2024 | globenewswire.comMaxCyte Expands Stock Capital with New IssuanceNovember 4, 2024 | markets.businessinsider.comMaxCyte’s Insider Stock Activity in FocusOctober 31, 2024 | markets.businessinsider.comMaxCyte to Participate in Two Upcoming Investor ConferencesOctober 31, 2024 | globenewswire.comMaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 SharesOctober 31, 2024 | insidertrades.comMaxCyte (MXCT) Scheduled to Post Quarterly Earnings on WednesdayMaxCyte (NASDAQ:MXCT) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=635048)October 30, 2024 | marketbeat.comMaxCyte adds biotech veteran Collins to boardOctober 17, 2024 | investing.comMaxCyte Appoints Cynthia Collins to its Board of DirectorsOctober 15, 2024 | globenewswire.comMaxCyte, Inc: MaxCyte Appoints Ali Soleymannezhad as Chief Commercial OfficerOctober 12, 2024 | finanznachrichten.deMaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024October 11, 2024 | globenewswire.comMaxCyte Appoints Ali Soleymannezhad as Chief Commercial OfficerOctober 10, 2024 | globenewswire.comMillennium Management LLC Sells 993,093 Shares of MaxCyte, Inc. (NASDAQ:MXCT)Millennium Management LLC lowered its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 16.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,177,953 shares of the company's stock after selling 993,093 sharOctober 5, 2024 | marketbeat.comMaxcyte: Reaching Financial Inflection With CASGEVY Ramp UpOctober 4, 2024 | seekingalpha.comStanley C. Erck Sells 21,607 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockOctober 3, 2024 | insidertrades.comInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 3,000 Shares of StockOctober 1, 2024 | insidertrades.comMassachusetts Financial Services Co. MA Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)Massachusetts Financial Services Co. MA cut its position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 80.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 499,635 shares of the company's stock after selling 2,025,September 23, 2024 | marketbeat.comMaxCyte, Inc: MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic DiseasesSeptember 16, 2024 | finanznachrichten.deMaxCyte touts strategic platform license deal with Kamau TherapeuticsSeptember 16, 2024 | lse.co.ukMaxCyte In Deal With Kamau Therapeutics To Boost Cell Therapy Development For Genetic DiseasesSeptember 16, 2024 | markets.businessinsider.comMaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic DiseasesSeptember 16, 2024 | globenewswire.comMaxCyte, Inc. (NASDAQ:MXCT) Director Sells $118,174.99 in StockSeptember 7, 2024 | insidertrades.comInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 29,767 Shares of StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director Stanley C. Erck sold 29,767 shares of the company's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total value of $118,174.99. Following the sale, the director now owns 269,118 shares of the company's stock, valued at $1,068,398.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.September 5, 2024 | marketbeat.comMaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing ConferenceSeptember 5, 2024 | globenewswire.comJohn Joseph Johnston Sells 3,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockAugust 29, 2024 | insidertrades.comMaxCyte (NASDAQ:MXCT) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPSMaxCyte (NASDAQ:MXCT - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.68% and a negative net margin of 83.00%. The firm had revenue of $10.43 million for the quarter, compared to analysts' expectations of $8.20 million. During the same period last year, the firm earned ($0.10) earnings per share.August 7, 2024 | marketbeat.comMXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024August 6, 2024 | investorplace.comMaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 GuidanceAugust 6, 2024 | globenewswire.comInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) EVP Sells 15,476 Shares of StockAugust 6, 2024 | insidertrades.comMaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross Sells 15,476 SharesMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) EVP Thomas M. Ross sold 15,476 shares of the company's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $4.54, for a total value of $70,261.04. Following the completion of the transaction, the executive vice president now directly owns 25,000 shares of the company's stock, valued at approximately $113,500. The sale was disclosed in a filing with the SEC, which can be accessed through this link.August 5, 2024 | marketbeat.comSwedbank AB Purchases Shares of 1,600,000 MaxCyte, Inc. (NASDAQ:MXCT)Swedbank AB purchased a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,600,000 shares of the company's stock, valued at approximaAugust 3, 2024 | marketbeat.comMXCT Oct 2024 2.500 put (MXCT241018P00002500)July 20, 2024 | finance.yahoo.comMXCT Aug 2024 2.500 put (MXCT240816P00002500)July 20, 2024 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Short Interest Up 19.4% in JuneMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 4,070,000 shares, a growth of 19.4% from the June 15th total of 3,410,000 shares. Based on an average daily trading volume, of 550,300 shares, the short-interest ratio is presently 7.4 days. Currently, 4.4% of the shares of the stock are short sold.July 16, 2024 | marketbeat.comChevy Chase Trust Holdings LLC Raises Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)Chevy Chase Trust Holdings LLC boosted its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 2,182.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,296,397 shares of the company's stoJuly 11, 2024 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross Sells 13,531 SharesJuly 11, 2024 | insidertrades.comMaxCyte, Inc. (NASDAQ:MXCT) EVP Sells $54,529.93 in StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) EVP Thomas M. Ross sold 13,531 shares of the company's stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $4.03, for a total transaction of $54,529.93. Following the sale, the executive vice president now owns 25,000 shares in the company, valued at $100,750. The sale was disclosed in a filing with the SEC, which is available at this link.July 10, 2024 | marketbeat.comMaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024July 9, 2024 | globenewswire.comMaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 10,000 SharesJuly 3, 2024 | insidertrades.comJohn Joseph Johnston Sells 10,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $3.99, for a total transaction of $39,900.00. Following the transaction, the director now owns 141,950 shares in the company, valued at approximately $566,380.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.July 1, 2024 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) EVP Sells $136,331.97 in StockJune 25, 2024 | insidertrades.comMaxCyte (NASDAQ:MXCT) Shares Up 10.3%MaxCyte (NASDAQ:MXCT) Trading Up 10.3%June 12, 2024 | marketbeat.comMaxCyte (NASDAQ:MXCT) Sees Strong Trading Volume After Insider Buying ActivityMaxCyte (NASDAQ:MXCT) Sees Strong Trading Volume on Insider Buying ActivityJune 11, 2024 | marketbeat.comMaher Masoud Acquires 29,557 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockJune 11, 2024 | insidertrades.com Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] MXCT Media Mentions By Week MXCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MXCT News Sentiment▼0.500.46▲Average Medical News Sentiment MXCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MXCT Articles This Week▼02▲MXCT Articles Average Week Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MeiraGTx News MacroGenics News Arcturus Therapeutics News Heron Therapeutics News Harvard Bioscience News AnaptysBio News Evolent Health News LegalZoom.com News TaskUs News Custom Truck One Source News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MXCT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
